Rapamycin extenuates experimental colitis by modulating the gut microbiota

Area of Science:

• Gastroenterology
• Microbiology
• Immunology

Background:

• Inflammatory bowel disease (IBD) pathogenesis involves complex interactions between autophagy and the gut microbiota.
• Dysbiosis and altered autophagy are key features of IBD, suggesting potential therapeutic targets.

Purpose of the Study:

• To investigate the therapeutic effects of rapamycin on experimental colitis.
• To elucidate the role of gut microbiota modulation in rapamycin's efficacy for inflammatory bowel disease.

Main Methods:

• Acute colitis was induced in mice using dextran sodium sulfate (DSS) and trinitrobenzenesulfonic acid.
• Mice were treated with rapamycin or hydroxychloroquine, and outcomes were assessed via clinical scores, histology, cytokine levels, and intestinal permeability.
• Gut microbiota composition was analyzed using 16S rRNA sequencing, and the role of the microbiome was further explored using antibiotic-induced depletion.

Main Results:

• Rapamycin treatment ameliorated colitis, reducing disease activity, improving colon length, and decreasing inflammatory markers (IL-6, TNF-α).
• Rapamycin intervention altered gut microbiota composition, increasing the abundance of beneficial bacteria like Lactobacillus and Mucispirillum.
• The therapeutic benefits of autophagy activation were diminished following gut microbiome depletion, highlighting the microbiome's critical role.

Conclusions:

• Rapamycin demonstrates therapeutic potential in experimental colitis, likely mediated through its influence on the gut microbiota.
• Targeting the gut microbiota in conjunction with autophagy modulation may represent a novel therapeutic strategy for inflammatory bowel disease.